En Es
Categories

Industry News


Seegene Collaborates with Thermo to Enter US Market

By Labmedica International staff writers
29 May 2017

Image: Seegene has entered into a collaboration with Thermo Fisher Scientific to focus on providing assays to the U.S. diagnostic market (Photo courtesy of iStock).Seegene Inc., a developer of multiplex molecular diagnostics technologies and assays, has entered into a collaboration with Thermo Fisher Scientific, in which Seegene will file for U.S. Food and Drug Administration (FDA) clearance of its Allplex diagnostic assay portfolio at the same time that Thermo Fisher files for FDA clearance to run Seegene's assays on Thermo Fisher's QuantStudio 5 Real-Time PCR System (PCR System).

Seegene develops high multiplex molecular diagnostic assays for the global market using its proprietary real-time PCR technologies. Seegene’s Allplex assay is capable of providing Ct values for multiple targets in a single tube or well and when combined with Thermo Fisher's PCR System, it will offer a comprehensive MDx solution. Seegene's portfolio of syndromic panel products, which includes various sexually transmitted infections, gastrointestinal, and respiratory pathogen detection assays, will be first introduced in the U.S. market. Thermo Fisher's dominant position in instrumentation will allow Seegene's multiplex detection technologies to establish a strong foothold in the U.S. market.

“The U.S. is the world's largest MDx market. Well versed in advanced detection technologies, it also has the strongest customer demands,” said Seegene's CEO, Dr. Jong-Yoon Chun. “The synergistic combination of Thermo Fisher's newest instrument and Seegene's powerful multiplex PCR chemistry technologies will enable us to gain U.S. market share by offering advanced detection methods to more physicians and patients.”

“We are proud to collaborate with Seegene as we move forward to seek FDA clearance for our respective platforms in parallel,” said Kim Kelderman, vice president and general manager of Genetic Analysis at Thermo Fisher Scientific. “We are committed to working with global partners who share our vision of driving better health outcomes.”



E-mail Print
FaceBook Twitter Google+ Linked in

Seegene

Seegene, Inc. is a developer of multiplex molecular technologies and multiplex clinical molecular diagnostics for infectious diseases, genetics, pharmacogenetics, and oncology. The company’s products detect multi-pathogens with high sensitivity, specificity and reproducibility, resulting in saving of time, labor and cost.
Gold member
More info

More articles about Seegene

19 Apr 2018
Seegene Unveils Combination Test at ECCMID 2018
Seegene Inc., a developer of multiplex PCR technologies, introduced a combination test at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2018) held in Madrid, Spain, from April 21 to 24, 2018. The combination test is a high-efficiency solution that diagnoses various causes of diseases with multiplex molecular diagnosis assays. Seegene also showcased its molecular diagnostic system SGSTAR (Seegene Sameday Test and Report), which allows order-to-report on the same day and enables the running of the combination test.
Read More
09 Jan 2018
Seegene Develops World’s First Multiplex MDx Assays with AI System
Seegene Inc., a developer of multiplex PCR technologies, successfully developed molecular diagnostics (MDx) assays in just four days using an artificial intelligence- (AI) based automated assay development system. These assays are high multiplex real-time PCR reagents developed completely by AI and are meant for the simultaneous detection of eight different DNA targets for each of meningitis and sexually transmitted infections.
Read More
28 Sep 2017
Seegene Partners with Hamilton to Develop Random Access System
Seegene, a developer of multiplex molecular technologies and multiplex clinical molecular diagnostics (M-MoDx), has signed a Memorandum of Understanding (MoU) with Hamilton Company, which designs and manufactures precision measurement devices, automated liquid handling workstations, and sample management systems, to develop the Seegene Random Access System.
Read More

Additional news

26 Jul 2021
GE Healthcare Backs Development of Innovative Total-Body PET/CT Scanner for Simultaneous Whole-Body Imaging
GE Healthcare (Chicago, IL, USA) is backing a collaboration among Quibim (Valenciana, Spain), Full Body Insight, and Oncovision (Valenciana, Spain) to build an innovative total-body PET/CT scanner for simultaneous whole-body imaging.
Read More
23 Jul 2021
RSNA 2021 to Be In-Person Event with Demonstrations of Latest Medical Imaging Technologies in CT, MRI and AI
The world's largest radiology forum is all set to offer robust in-person scientific assembly and technical exhibition with demonstrations of the latest medical imaging technologies in CT, MRI, artificial intelligence (AI), 3D printing and more.
Read More
21 Jul 2021
BD Seeks to Transform Patient Experience Through Vision of 'One-Stick Hospital Stay'
Becton, Dickinson and Company (BD Franklin Lakes, NJ, USA) has taken a large step forward in transforming the patient experience through a vision of a "One-Stick Hospital Stay," building on its history of innovation and leadership in blood collection and vascular access solutions.
Read More
19 Jul 2021
ELITechGroup Acquires Freezing Point Osmometry Provider GONOTEC
ELITechGroup (Puteaux, France) has acquired GONOTEC (Berlin, Germany), thus uniting two osmometry market leaders.
Read More
16 Jul 2021
DiaSorin Completes Acquisition of Luminex to Become a Full-Fledged Diagnostic and Life Science Player
DiaSorin S.p.A. (?Saluggia?, Italy) has completed the acquisition of Luminex Corporation (Austin, TX, USA), allowing it to gain access to Luminex’s multiplexing technology and a portfolio that will strengthen its existing offering, while expanding the Group presence in the US.
Read More
14 Jul 2021
Global Smart Hospitals Market to Reach USD 221.3 Billion by 2030 Due to Proliferation of ML, AI and IoT
The global smart hospitals market is expected to reach USD 221.3 billion by the end of 2030 due to health professionals increasing their usage of electronic health records and connected medical assistance.
Read More
13 Jul 2021
AI Diagnostic Tool Analyzes CT Scans to Spot Prostate Cancer Before Patients Have Symptoms
Researchers have developed a diagnostic tool that can spot prostate cancer before patients have any symptoms, using artificial intelligence to analyze Computed Tomography (CT) scans in just seconds.
Read More
13 Jul 2021
Instrumentation Laboratory, Inova Diagnostics and Biokit Organizationally Transform and Now Share Werfen Name
Werfen (Barcelona, Spain) companies, including Instrumentation Laboratory (IL), Inova Diagnostics (Inova), and Biokit, are uniting under one name and one brand - Werfen. As part of this effort, the company has completed organizational transitions and adopted a new global brand identity, including a new corporate logo.
Read More
08 Jul 2021
Global AI-Based Surgical Robots Market to Reach USD 17.2 Billion by 2028
The global AI-based surgical robots market size is expected to expand at a CAGR of 17.2% from 2021 to 2028 to reach USD 17.2 billion by 2028, driven by increased efficiency and success rate offered by robotic surgeries, along with a shift in the preference for minimally invasive surgeries by patients over traditional methods.
Read More
Copyright © 2000-2021 TradeMed.com. All rights reserved. | Terms And Conditions